Explore the Novartis T-Charge™ platform, a rapid cell manufacturing process that:
Preserves naive T-cell stemness in the final product<sup>1-3</sup>Preserves naive T-cell stemness in the final product<sup>1-3</sup>
Preserves naive T-cell stemness in the final product1-3
which may increase the stem and central memory T cells3
<span>Has a simplified manufacturing process with <br/> minimal ex vivo culture<sup>2,3</sup></span><span>Has a simplified manufacturing process with <br/> minimal ex vivo culture<sup>2,3</sup></span>
Has a simplified manufacturing process with
minimal ex vivo culture2,3
<span>Has &lt; 2 days manufacturing time<sup>2,3</sup></span><span>Has &lt; 2 days manufacturing time<sup>2,3</sup></span>
Has < 2 days manufacturing time2,3
Tap to begin
T-Charge™ is an investigational manufacturing platform and there is no guarantee
that it will become commercially available for the use(s) under investigation.

MOA is based on in vitro/in vivo data.